Specifically, SFRP2 hypermethylation (and consequent loss of SFRP2 expression) has widely been documented in several cancer types, such as gastric cancer [10], osteosarcoma [11], and breast cancer [12]. Here, SFRP2 is linked to breast carcinoma.